| Literature DB >> 29706646 |
Wojciech Wiszniewski1,2,3, Pawel Gawlinski4, Tomasz Gambin4,5, Monika Bekiesinska-Figatowska6, Ewa Obersztyn4, Dorota Antczak-Marach7, Zeynep Hande Coban Akdemir8, Tamar Harel8, Ender Karaca8, Marta Jurek4, Katarzyna Sobecka4, Beata Nowakowska4, Malgorzata Kruk7, Iwona Terczynska7, Alicja Goszczanska-Ciuchta7, Mariola Rudzka-Dybala7, Ewa Jamroz9, Antoni Pyrkosz10, Anna Jakubiuk-Tomaszuk11, Piotr Iwanowski12, Dorota Gieruszczak-Bialek12,13, Malgorzata Piotrowicz14, Maria Sasiadek15, Iwona Kochanowska16, Barbara Gurda17, Barbara Steinborn17, Mateusz Dawidziuk4, Jennifer Castaneda4, Pawel Wlasienko4, Natalia Bezniakow4, Shalini N Jhangiani18, Dorota Hoffman-Zacharska4, Jerzy Bal4, Elzbieta Szczepanik7, Eric Boerwinkle18,19, Richard A Gibbs18, James R Lupski8,18,20,21.
Abstract
Malformations of cortical development (MCDs) manifest with structural brain anomalies that lead to neurologic sequelae, including epilepsy, cerebral palsy, developmental delay, and intellectual disability. To investigate the underlying genetic architecture of patients with disorders of cerebral cortical development, a cohort of 54 patients demonstrating neuroradiologic signs of MCDs was investigated. Individual genomes were interrogated for single-nucleotide variants (SNV) and copy number variants (CNV) with whole-exome sequencing and chromosomal microarray studies. Variation affecting known MCDs-associated genes was found in 16/54 cases, including 11 patients with SNV, 2 patients with CNV, and 3 patients with both CNV and SNV, at distinct loci. Diagnostic pathogenic SNV and potentially damaging variants of unknown significance (VUS) were identified in two groups of seven individuals each. We demonstrated that de novo variants are important among patients with MCDs as they were identified in 10/16 individuals with a molecular diagnosis. Three patients showed changes in known MCDs genes and a clinical phenotype beyond the usual characteristics observed, i.e., phenotypic expansion, for a particular known disease gene clinical entity. We also discovered 2 likely candidate genes, CDH4, and ASTN1, with human and animal studies supporting their roles in brain development, and 5 potential candidate genes. Our findings emphasize genetic heterogeneity of MCDs disorders and postulate potential novel candidate genes involved in cerebral cortical development.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29706646 PMCID: PMC6057976 DOI: 10.1038/s41431-018-0137-z
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246